|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
FY2020
12 months to Dec 31, 2020
|
FY2019
12 months to Dec 31, 2019
|
|
|---|---|---|---|---|---|
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Depreciation and amortization | |||||
| Gain on forgiveness of PPP loan | |||||
| Paycheck Protection Program CARES Act | |||||
| Total gain on forgiveness of PPP loan | |||||
| Credit loss expense | |||||
| Provision for inventory obsolescence | |||||
| Stock compensation to employees | |||||
| Stock compensation to nonemployees | |||||
| Stock-based compensation | |||||
| Increase or decrease in: | |||||
| Accounts receivable | |||||
| Inventory | |||||
| Prepaid clinical expenses | |||||
| Prepaid insurance and services | |||||
| Other | |||||
| Accounts payable and accrued expenses | |||||
| Total adjustments | |||||
| NET CASH USED IN OPERATING ACTIVITIES | |||||
| CASH FLOWS FROM INVESTING ACTIVITIES | |||||
| Purchases of furniture and equipment | |||||
| Collections from mortgage note receivable | |||||
| NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES | |||||
| CASH FLOWS FROM FINANCING ACTIVITIES | |||||
| Proceeds from sale of common stock and warrants, net of issuance costs | |||||
| Net proceeds from sale of stock | |||||
| Net proceeds from merger recapitalization | |||||
| Merger recapitalization transaction costs | |||||
| Exercise of stock options | |||||
| Net from sale of warrants | |||||
| Exercise of warrants | |||||
| Payments on PPP loan | |||||
| Refund of PPP loan payments | |||||
| NET CASH PROVIDED BY FINANCING ACTIVITIES | |||||
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | |||||
| CASH AND CASH EQUIVALENTS, beginning of year | |||||
| CASH AND CASH EQUIVALENTS, end of year | |||||
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | |||||
| Cash paid for interest | |||||
| Issuance of common stock for services | |||||
| Liabilities assumed, net of non-cash assets received in merger recapitalization | |||||
Loading...